Group 1 - The core viewpoint of the article highlights that the company, 泰恩康 (301263), is accelerating the clinical development of CKBA in response to national policies supporting pharmaceutical innovation [1] Group 2 - For the adult vitiligo indication, the company is steadily advancing the application process for the Phase III clinical trial [1] - The application for the Phase II clinical trial for the 2-12 years old children's vitiligo indication has been accepted by the drug regulatory authority, and the company will disclose updates if approved [1] - CKBA has obtained the seamless adaptive clinical trial approval for the Phase II/III indication of rosacea, and the company is actively preparing for ethical review and subject enrollment [1]
泰恩康：公司正加速推进CKBA的临床研发进程